NovoCure Limited (NVCR)
NASDAQ: NVCR · Real-Time Price · USD
12.81
-0.01 (-0.08%)
At close: Oct 31, 2025, 4:00 PM EDT
12.95
+0.14 (1.08%)
After-hours: Oct 31, 2025, 4:46 PM EDT
NovoCure Revenue
NovoCure had revenue of $167.20M in the quarter ending September 30, 2025, with 7.81% growth. This brings the company's revenue in the last twelve months to $642.27M, up 11.17% year-over-year. In the year 2024, NovoCure had annual revenue of $605.22M with 18.82% growth.
Revenue (ttm)
$642.27M
Revenue Growth
+11.17%
P/S Ratio
2.20
Revenue / Employee
$431,632
Employees
1,488
Market Cap
1.43B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 605.22M | 95.88M | 18.82% |
| Dec 31, 2023 | 509.34M | -28.50M | -5.30% |
| Dec 31, 2022 | 537.84M | 2.81M | 0.53% |
| Dec 31, 2021 | 535.03M | 40.66M | 8.23% |
| Dec 31, 2020 | 494.37M | 143.05M | 40.72% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| Eli Lilly and Company | 59.42B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.11B |
NVCR News
- 1 day ago - NovoCure Limited (NVCR) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 1 day ago - Novocure Reports Third Quarter 2025 Financial Results - Business Wire
- 14 days ago - NovoCure: Buy Rating As Pipeline Gains Drive Renewed Momentum - Seeking Alpha
- 16 days ago - Novocure to Present New Research for Tumor Treating Fields (TTFields) Therapy at European Association of Neuro-Oncology (EANO) Meeting and the European Society for Medical Oncology (ESMO) Congress - Business Wire
- 4 weeks ago - Novocure to Report Third Quarter 2025 Financial Results - Business Wire
- 4 weeks ago - Novocure to Present Final Results from the Pivotal Phase 3 METIS Trial of its Tumor Treating Fields (TTFields) Therapy for Brain Metastases from Non-Small Cell Lung Cancer at 2025 ASTRO Annual Meeting - Business Wire
- 6 weeks ago - Novocure's Optune Lua® Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC) - Business Wire
- 7 weeks ago - NovoCure Limited (NVCR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript) - Seeking Alpha